Construction and validation of a novel prognostic nomogram for patients with poorly differentiated gastric neuroendocrine neoplasms

Table 1 Clinicopathological characteristics of 336 patients, n (%)

Clinicopathological characteristics	n (%)
Age (year), mean ± SD	62.7 ± 9.35
BMI (kg/m2), mean ± SD	4.7 ± 2.40
Gender
Male	277 (82.4)
Female	59 (17.6)
Smoking history
Yes	143 (42.6)
No	193 (57.4)
Drinking history
Yes	142 (42.3)
No	194 (57.7)
Pathological grade
NEC	227 (67.6)
MANEC	109 (32.4)
CgA
Positive	230 (68.5)
Negative	106 (31.5)
Syn
Positive	324 (96.4)
Negative	12 (3.6)
CD56
Positive	271 (80.7)
Negative	65 (19.3)
Vascular cancer
Yes	117 (34.8)
No	219 (65.2)
Perineural invasion
Yes	64 (19.0)
No	272 (81.0)
Ki-67 index (%)
< 70	104 (31.0)
≥ 70	232 (69.0)
Tumor diameter (cm)
< 3	45 (13.4)
≥ 3	291 (86.6)
Tumor morphology
Uplift	52 (15.5)
Ulcer	272 (81.0)
Others	12 (3.5)
Tumor location
Upper third	199 (59.2)
Middle third	53 (15.8)
Lower third	78 (23.2)
Others	6 (1.8)
Invasion depth
T1	27 (8.0)
T2	41 (12.3)
T3	111 (33.0)
T4	157 (46.7)
Lymph node metastasis
N0	77 (22.9)
N1	77 (22.9)
N2	86 (25.6)
N3	96 (28.6)
Distant metastasis
M0	275 (81.8)
M1	61 (18.2)
TNM stage
I stage	48 (14.3)
II stage	83 (24.7)
III stage	144 (42.9)
IV stage	61 (18.1)
PLR
Low-PLR	193 (57.4)
High-group	143 (42.6)
FBG
Low-FBG	218 (64.9)
High-FBG	118 (35.1)

BMI: Body mass index; NEC: Neuroendocrine carcinoma; MANEC: Mixed adeno-neuroendocrine carcinoma; CgA: Chromogranin A; Syn: Synuclein; TNM: Tumor-node-metastasis; PLR: Platelet-to-lymphocyte ratio; FBG: Fibrinogen.